Bayer Launches Test Your Cancer Campaign

Empowering patients to see the real picture through genomic cancer testing

Originally Published by Bayer.

Bayer announces the launch of Test Your Cancera global educational campaign that harnesses the creative power of imagination to help cancer patients better understand that genomic cancer testing is a crucial step in a diagnosis, painting a more precise picture of a person’s individual cancer.

Only 25 percent of cancer patients and caregivers report discussing genomic cancer testing with their doctor.1 The results of genomic cancer testing can identify changes in DNA, known as genomic alterations, within cancer cells that determine how a tumor behaves or why it grows. Studies show that 30-49 percent of patients who undergo genomic cancer testing have an alteration that can be matched with approved or investigational treatments.2,3

Cancer diagnoses have traditionally been associated with the tumor location. In the age of precision medicine, physicians now have more information, made available through genomic cancer testing that may change a patient’s treatment journey. One example is Bryce Olson, a national advocate and cancer survivor, who is supporting Bayer’s educational launch by sharing his story. At 44 years old, Olson was diagnosed with advanced cancer. He faced a poor prognosis and started to lose hope. Then he learned about genomic cancer testing.

“The moment I learned about the role of genomic cancer testing in precision medicine, I demanded it for myself and that action transformed my cancer story; it’s the reason I’m still alive today,” said Olson. “My advice to any patient facing a cancer diagnosis; get your cancer tested genomically and see what’s driving your specific cancer.”

For cancer patients, it is important to understand the differences between genomic cancer testing and genetic testing. For example, a genomic cancer test can be useful to understand what is causing a patient’s tumor to grow and spread, while a genetic test helps identify inherited gene mutations that pose an increased risk of having cancer.4,5

Patients living with cancer are central to this campaign as they talk about how genomic cancer testing helped them see the real picture. The initiative also provides educational content to guide patients during conversations with their doctors (http://www.testyourcancer.com/). Anyone touched by cancer is encouraged to join the movement by sharing the videos, website content, and using the hashtag #TestYourCancer on social media.

“Genomic cancer testing allows physicians to create a more individualized treatment plan for the patient based on their cancer,” said Robert LaCaze, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of the Oncology Strategic Business Unit at Bayer. “During this important time when innovation in cancer treatment is rapidly evolving, Bayer is encouraging genomic cancer testing from the start of a diagnosis, in order to make well-informed treatment decisions based on the patient’s cancer.”

The Test Your Cancer campaign makes available a suite of educational materials including a brochure, patient-doctor discussion guide, fact sheet describing what occurs during a genomic cancer test, and an infographic explaining how genomic cancer testing differs from genetic testing.

Latest News

NOD Forum: Honoring the Disability Rights Movement

The road to disability rights has been a long one. One that started long before the Americans with Disabilities Act (ADA) of 1990 was passed. In celebration of 40 years of the National Organization on Disability, disability leaders, supporters and activists gathered in Washington, D.C last week to discuss the…

5 Biggest News Stories of the Week: September 29

As the saying goes, the news never stops — but there’s a lot of it out there, and all of it doesn’t always pertain to our readers. In this weekly news roundup, we’ll cover the top news stories that matter most to our diversity focused audience. 1. Research Outlines Lack…

Humana Ranks Highly in the Hispanic Association on Corporate Responsibility Inclusion Index

Originally published at press.humana.com. Humana ranked No. 9 on The DiversityInc Top 50 Companies for Diversity list in 2022.   Humana Inc. celebrates the high rankings it recently received in the 2022 Hispanic Association on Corporate Responsibility (HACR) Corporate Inclusion Index (CII), a research initiative that measures Hispanic inclusion in the…